18 and older, any sex, with Sarcoma, Soft Tissue or Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Clinical Benefit RatePrimary· 16 weeks
Clinical benefit rate = complete response (CR) + partial response (PR) + stable disease (SD)
* CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.
* PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
* SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Group
Value
95% CI
Pazopanib
22
Progression-free Survival (PFS)Secondary· Until disease progression (median follow-up of 10.83 months with full range 0.787-42.26 months)
PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).
Group
Value
95% CI
Pazopanib
3.67
2.62 – 7.25
Overall Survival (OS)Secondary· Until death (median follow-up of 10.83 months with full range 0.787-42.26 months)
Group
Value
95% CI
Pazopanib
14.16
8.46 – NA
Median Overall Change in Quality of LifeSecondary· Change from baseline to end of treatment (median length of treatment 70 days (5-515 days)))
* Quality of life will be measured using the Functional Assessment of Cancer Therapy-General (FACT-G7) validated survey
* 7 statements where the participant can indicate 0 (not at all) up to 4 (very much). The statements include 1) I have lack of energy; 2) I have pain; 3) I have nausea; 4) I worry that my condition will get worse; 5) I am sleeping well; 6) I am able to enjoy life; 7) I am content with the quality of my life right now.
* The first 4 statements will negatively affect the total score and the last 3 statements will positively affect the total score
* Each item is scored and then
Group
Value
95% CI
Pazopanib
2
0.7356979 – 4.5834510
Adverse events — posted to ClinicalTrials.gov
Time frame: -Reportable adverse events were tracked for 30 days following the last day of study treatment. Median treatment length was 70 days (5 days-515 days). As of first reporting of results, one participant is still receiving treatment..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Pazopanib
Serious: 27/56 (48%)
Deaths: 24/56
Serious adverse events (34 terms)
Reaction
System
Pazopanib
Alanine aminotransferase increased
Metabolism and nutrition disorders
—
Pneumothorax
Respiratory, thoracic and mediastinal disorders
—
Thromboembolic event
Vascular disorders
—
Heart failure
Cardiac disorders
—
Colitis
Infections and infestations
—
Lung infection
Infections and infestations
—
Dehydration
Metabolism and nutrition disorders
—
Generalized muscle weakness
Musculoskeletal and connective tissue disorders
—
Pleural effusion
Respiratory, thoracic and mediastinal disorders
—
Acute coronary syndrome
Cardiac disorders
—
Atrial flutter
Cardiac disorders
—
Sinus tachycardia
Cardiac disorders
—
Anal hemorrhage
Gastrointestinal disorders
—
Bowel infarction related to disease
Gastrointestinal disorders
—
Colonic fistula
Gastrointestinal disorders
—
Diarrhea
Gastrointestinal disorders
—
GI bleed
Gastrointestinal disorders
—
Jejunal perforation
Gastrointestinal disorders
—
Nausea
Gastrointestinal disorders
—
Pancreatitis
Gastrointestinal disorders
—
Upper gastrointestinal hemorrhage
Gastrointestinal disorders
—
Fatigue
General disorders
—
Bronchial infection
Infections and infestations
—
Fall
Injury, poisoning and procedural complications
—
Fracture
Injury, poisoning and procedural complications
—
Other adverse events (104 terms — click to expand)
Pazopanib is FDA approved as a second line and beyond treatment for metastatic soft tissue sarcoma. There is a population of elderly and debilitated soft tissue sarcoma patients that are not fit for standard first line chemotherapy that is doxorubicin based. As pazopanib is well tolerated with minimal side effects, the investigators propose a phase II study to evaluate pazopanib as a first-line agent in patients with non-resectable or metastatic disease who are not candidates for cytotoxic chemotherapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A
· Phase 1
· not yet recruiting
NCT07087158 — A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
· Phase 2
· not yet recruiting
NCT04199026 — Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sa
· NA
· recruiting
NCT03850730 — Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia
· Phase 1, PHASE2
· unknown
NCT05432791 — Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped W
· Phase 2, PHASE3
· active not recruiting
Other recruiting trials for Sarcoma, Soft Tissue
Currently open trials in the same condition.
NCT07071727 — Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas
· NA
· recruiting
NCT06873685 — Soft Tissue Sarcoma: Motor Performance, Robotic Rehabilitation, Nutrition, and Quality of Life
· NA
· recruiting
Other Washington University School of Medicine trials
Trials by the same sponsor.
NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
· Phase 2
· not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer
· Phase 2
· not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
· Phase 1
· not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients
· not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial)
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 5 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02300545.